Lazard Asset Management LLC Invests $4.39 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Lazard Asset Management LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 82,005 shares of the company's stock, valued at approximately $4,390,000. Lazard Asset Management LLC owned 0.16% of Janux Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the last quarter. Avanza Fonder AB purchased a new stake in Janux Therapeutics during the fourth quarter valued at approximately $139,000. Meeder Asset Management Inc. acquired a new stake in Janux Therapeutics in the 4th quarter worth approximately $159,000. Tower Research Capital LLC TRC increased its position in shares of Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after acquiring an additional 3,436 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at $221,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Down 0.9%

Shares of NASDAQ JANX traded down $0.24 during mid-day trading on Wednesday, reaching $25.17. The company had a trading volume of 204,648 shares, compared to its average volume of 866,701. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71. The stock has a market cap of $1.49 billion, a P/E ratio of -21.56 and a beta of 3.24. The firm has a 50 day simple moving average of $28.38 and a two-hundred day simple moving average of $40.22.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction dated Friday, March 7th. The shares were purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares of the company's stock, valued at approximately $314,582,722.74. The trade was a 1.10% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 10,001 shares of company stock worth $313,964. 29.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JANX. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.